Aktienanalyse zu Travere Therapeutics Inc (TVTX)TVTXTravere Therapeutics Inc

Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Travere Therapeutics Inc is a good buy right now due to its strong revenue growth of 48% year-over-year in Q2 2026, reaching $169 million, and a solid gross margin of 96.45%. The stock has a favorable analyst price target range of $75 to $78, suggesting a potential upside of 14% to 19% from the current price. However, the main risk is the significant net loss of $34.79 million reported for Q2 2026, which indicates ongoing financial challenges that could affect future performance.